SCHEMBL1962408

SCHEMBL1962408

COCCS(=O)(=O)c1ccc(B(O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.52
LOX P28300 1/20 0.47
HTT P42858 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LPL P06858 6/20 0.41
LIPG Q9Y5X9 6/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
KCNH2 Q12809 1/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MMP8 P22894 1/20 0.39
MMP13 P45452 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL299031 0.80 ENPP2 (0.57) ENPP2HTTLPLLIPGCA1
SCHEMBL8521424 0.80 LOX (0.50) ENPP2LOXHTTNPSR1CA1
SCHEMBL5859628 0.80 PSIP1 (0.56) LOXHTTNPSR1ALDH1A1MAPT
SCHEMBL385294 0.79 ALDH1A1 (0.69) ENPP2HTTALDH1A1MAPTLMNA
SCHEMBL20300431 0.79 CA2 (0.50) LOXHTTNPSR1CA1CA2
SCHEMBL564467 0.78 ALDH1A1 (0.64) LOXHTTALDH1A1MAPTLMNA
SCHEMBL248212 0.77 ENPP2 (0.63) ENPP2LPLLIPGCA1CA2
SCHEMBL29953691 0.77 CA2 (0.55) ENPP2LPLLIPGCA1CA2
SCHEMBL1939147 0.77 PLCG1 (0.55) LOXKCNH2ALDH1A1MAPTLMNA
SCHEMBL17394071 0.76 ENPP2 (0.52) ENPP2HTTLPLLIPGCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 ENPP2 794/4885LOX 1669/4885HTT 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.